27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
The Sustainable Markets Initiative (SMI), a network of global CEOs and private sector corporations targeting planet-friendly growth, has created a new task force focused on the healthcare sector. 4 November 2021
Takeda was the only pharma heavyweight to announce an acquisition in October, but a few smaller drugmakers did deals to create larger entities, too. 4 November 2021
Swiss rare diseases specialist Santhera Pharmaceuticals today said it has appointed Stephanie Brown as president North America and a member of its executive management team, effective December 1. 4 November 2021
The coronavirus vaccine developed by Bharat Biotech, Covaxin, has been approved by the World Health Organization (WHO) under its emergency use listing (EUL) process. 4 November 2021
Novartis has agreed to sell 53.3 million (around 33%) bearer shares of fellow Swiss pharma giant Roche in a bilateral transaction to Roche for a total consideration of $20.7 billion. 4 November 2021
Cardiopulmonary diseases focussed US firm PhaseBio Pharmaceuticals saw its shares close down nearly 6% and fall a further 2.9% to $3.93 after-hours yesterday, despite positive mid-stage results for its bentracimab. 4 November 2021
The European Medicines Agency has terminated its rolling review of Eli Lilly’s coronavirus treatments bamlanivimab and etesevimab, at the company’s request. 3 November 2021
Biotech funder and incubator Flagship Pioneering today announced a first-of-its-kind strategic partnership with the Cystic Fibrosis Foundation and Flagship's Pioneering Medicines to develop therapeutics that address the unmet needs of people living with cystic fibrosis by leveraging the innovations and teams of multiple Flagship-founded companies. 3 November 2021
Copycat biologics are helping to expand access to care for cancer patients, according to a report from the Association for Accessible Medicines (AAM), which represents the USA’s generics and biosimilars companies. 3 November 2021
US biopharma Vertex Pharmaceuticals recorded product revenues of $1.98 billion in the third quarter, the firm’s latest financial results show. 3 November 2021
Emerging biotech GRO Biosciences (GRObio), which is leveraging ground-breaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing totaling $25 million co-led by Leaps by Bayer and Redmile Group. 3 November 2021
US CNS-focussed drug biotech Amylyx Pharmaceuticals says it has now submitted a New Drug Application (NDA) to the US Food and Drug Administration for AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). 3 November 2021
California’s Amgen has reported third-quarter financial results showing total revenues increased 4% to $6.71 billion, driven by higher demand. 3 November 2021
Denmark-based diabetes care giant Novo Nordisk today reported financial results, showing that n the first nine months of 2021 operating profit was 45.01 billion Danish kroner ($5.34 billion), an increase of 5% in kroner terms and up 12% at constant exchange rates (CER). 3 November 2021
US mRNA-based biotech Moderna has entered into a strategic research and development collaboration with Metagenomi focused on advancing new gene editing systems for in vivo human therapeutic applications. 3 November 2021
Cambridge, UK-based biopharma start-up Dunad Therapeutics today signed its first deal in the growing area of interest in protein degraders, entering a license agreement with Swiss pharma giant Novartis to generate orally bioavailable covalent and protein degrading small molecule drugs. 2 November 2021
UK oncology-focussed biotech ValiRx has entered into a non-binding letter of intent (LoI) with TheoremRx, a recently incorporated US company, a next generation drug developer, to enter into a license agreement on pre-agreed terms to sub-license ValiRx' legacy asset VAL201 for development in the treatment of cancer. 2 November 2021
The value of influenza vaccines purchases in Russia in January-September of the current year increased by almost 25%, to 14.5 billion roubles ($211 million), according to recent statements by the Russian Ministry of Health and some local media, reports The Pharma Letter’s local correspondent. 2 November 2021
Investors appeared unimpressed by changes to the leadership team at US oncology specialist Mirati Therapeutics, where former Ipsen boss David Meek took over as chief executive in September of this year. 2 November 2021